DiaSys introduces dedicated respons and BioMajesty JCA-BM6010/C kits for Procalcitonin FS
After two years of successful marketing of Procalcitonin FS, dedicated kits for the DiaSys respons systems and BioMajesty JCA-BM6010/C will be available from October 2022. Procalcitonin FS offers a reliable alternative, when time matters in sepsis management.
for the determination of procalcitonin (PCT) in serum and plasma on automated photometric systems.
PCT is a sensitive marker for bacterial infections and sepsis, which is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection. It is a global health concern and a leading cause of death in hospitals worldwide, affecting an estimate of 48.9 million people each year.
The DiaSys assay offers high precision at clinical cut-off levels and a measuring range from 0.27 ng/mL (LoD depending on the analyzer) to 50 ng/mL. No prozone effect is observed up to 1000 ng/mL. Furthermore, Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management. Additionally, the assay shows good concordance to established methods.
The new dedicated kits are provided with CE marked applications for respons920, respons940 and BioMajesty JCA-BM6010/C. The respons kit offers 120 tests per kit, the BioMajesty JCA-BM6010/C kit 320 (2 x 160) tests per kit.
